Jedd D. Wolchok
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunology top 0.01%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Papers in
- Oncology 371
- Cancer Immunotherapy and Biomarkers 287
- CAR-T cell therapy research 163
- Cutaneous Melanoma Detection and Management 35
- Immunology 297
- Immunotherapy and Immune Responses 222
- Immune Cell Function and Interaction 88
- T-cell and B-cell Immunology 62
- Immune cells in cancer 27
- Co-authors
- Antoni Ribas (13 shared papers)Margaret K. Callahan (52 shared papers)Michael Andrew Postow (80 shared papers)Frank Stephen Hodi (47 shared papers)Taha Merghoub (91 shared papers)James Patrick Allison (26 shared papers)Jeffrey S. Weber (27 shared papers)Weiping Zou (1 shared paper)
- Journals
- Journal of Clinical Oncology (33 papers)Clinical Cancer Research (30 papers)Journal for ImmunoTherapy of Cancer (30 papers)Annals of Oncology (30 papers)New England Journal of Medicine (18 papers)
- Partner nations
- United StatesFranceItaly
In The Last Decade
Jedd D. Wolchok
549 papers receiving 163.8k citations
Jedd D. Wolchok's Hit Papers
Peers
Comparison fields: 5 of 192
- Oncology 105.0k
- Immunology 61.7k
- Cancer Research 14.3k
- Pulmonary and Respiratory Medicine 22.9k
- Molecular Biology 37.4k
Countries citing papers authored by Jedd D. Wolchok
This map shows the geographic impact of Jedd D. Wolchok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jedd D. Wolchok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jedd D. Wolchok more than expected).
Fields of papers citing papers by Jedd D. Wolchok
This network shows the impact of papers produced by Jedd D. Wolchok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jedd D. Wolchok. The network helps show where Jedd D. Wolchok may publish in the future.
Co-authors
The 25 scholars most cited alongside Jedd D. Wolchok, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 564 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma Hit paper breakdown → | 2010 | 12635 |
| 2 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma Hit paper breakdown → | 2015 | 6916 |
| 3 | Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer Hit paper breakdown → | 2015 | 6617 |
| 4 | Cancer immunotherapy using checkpoint blockade Hit paper breakdown → | 2018 | 5298 |
| 5 | Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2017 | 4597 |
| 6 | Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma Hit paper breakdown → | 2011 | 3746 |
| 7 | Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma Hit paper breakdown → | 2014 | 3649 |
| 8 | Nivolumab plus Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2013 | 3591 |
| 9 | Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET Hit paper breakdown → | 2012 | 3171 |
| 10 | Tumor mutational load predicts survival after immunotherapy across multiple cancer types Hit paper breakdown → | 2019 | 3019 |
| 11 | Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Hit paper breakdown → | 2018 | 2972 |
| 12 | Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma Hit paper breakdown → | 2013 | 2928 |
| 13 | Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2019 | 2848 |
| 14 | Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria Hit paper breakdown → | 2009 | 2660 |
| 15 | Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade Hit paper breakdown → | 2016 | 2528 |
| 16 | Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma Hit paper breakdown → | 2015 | 2365 |
| 17 | Immune Checkpoint Blockade in Cancer Therapy Hit paper breakdown → | 2015 | 2289 |
| 18 | PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations Hit paper breakdown → | 2016 | 2044 |
| 19 | iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics Hit paper breakdown → | 2017 | 1874 |
| 20 | Antibody therapy of cancer Hit paper breakdown → | 2012 | 1817 |
About Jedd D. Wolchok
Jedd D. Wolchok is a scholar working on Oncology, Immunology, Cancer Research, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 564 papers that have together received 167.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (287 papers), Immunotherapy and Immune Responses (222 papers), CAR-T cell therapy research (163 papers), Immune Cell Function and Interaction (88 papers), T-cell and B-cell Immunology (62 papers), Melanoma and MAPK Pathways (49 papers), Cutaneous Melanoma Detection and Management (35 papers) and Immune cells in cancer (27 papers). The work is most often cited by research in Oncology (105.0k citations), Immunology (61.7k citations), Cancer Research (14.3k citations), Pulmonary and Respiratory Medicine (22.9k citations) and Molecular Biology (37.4k citations). Jedd D. Wolchok has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Antoni Ribas, Margaret K. Callahan, Michael Andrew Postow, Frank Stephen Hodi, Taha Merghoub, James Patrick Allison, Jeffrey S. Weber, Weiping Zou, Lieping Chen and Lloyd J. Old. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Journal for ImmunoTherapy of Cancer, Annals of Oncology and New England Journal of Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.